Have Questions? Call Us Toll Free (877) 880-5251

News

August is Children?s Eye Health and Safety Month [caption id="attachment_175" align="alignright" width="300"]
[caption id="attachment_155" align="alignleft" width="114"]
[caption id="attachment_130" align="alignright" width="200"] Eyeglasses are only p
If you haven't joined Facebook yet, you're missing out on my Ask The Eye Doctor group. (not to mention all the people from high school who you've long forgotten!) Let's face it - we all have questions when we go to th
Are you concerned about the state of musical education in our country? If so, I must share with all of you a speech given last week by Wynton Marsalis. Marsalis, who has won a Pulitzer Prize in Music a
[caption id="attachment_112" align="alignright" width="300"] DNA[/caption] Just three years after the discovery of some of the genet
Newspapers are always looking for the next great story for excitement and to garner read
Eastern medicine gets a pat on the back for telling us all along that everythin
[caption id="attachment_43" align="alignleft" width="300" caption="Neural precursor cells derived from human embryonic stem cells, as seen from a microscope."]
As this season's football teams celebrated their respective division championships with champagne, with corks flying around the room painting each others' faces with the pressurized spray, I was motivated to warn my readers about avoiding a potentially devastating eye injury. Just three months ag
Poor Genentech. The company is making the news frequently these days. And it?s not about new drug discoveries or other scientific breakthroughs that is earning the company such press, but rumors of the compan
Welcome to the VisiVite Blog, featuring subjects about eye health and alternative treatments for macular degeneration and dry eye syndrome, in particular.? My intention for the blog is to discuss the the latest eye health news, eye care research, and alternative eye treatment solutions. I also hope
It seems highly unlikely that one company would produce two drugs, at different prices, that treat the same ailment, and be in the middle of a medical industry dispute, but that's exactly the case of Genentech Inc. Lucentis, a federally approved drug for the most severe form of macular degenerati
A recent study shared at the Meeting of the American Physical Society of Fluid Dynamic pointed towards inefficient fluid mixing of the medication and the gel within the eye being responsib

Search VisiVite